REGENERON PHARMACEUTICALS, INC. Cash And Cash Equivalents At Carrying Value

Quick Answer

REGENERON PHARMACEUTICALS, INC. reported Cash And Cash Equivalents At Carrying Value of $3.12 billion for the year ending 2025.

  • REGENERON PHARMACEUTICALS, INC. showed an increase of +25.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
  • XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 16 years of available data (2010 to 2025), REGENERON PHARMACEUTICALS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 2,669.9%.
  • Historical annual values: Fiscal year 2025: $3.12 billion | Fiscal year 2024: $2.49 billion | Fiscal year 2023: $2.73 billion | Fiscal year 2022: $3.11 billion | Fiscal year 2021: $2.89 billion | Fiscal year 2020: $2.19 billion | Fiscal year 2019: $1.62 billion | Fiscal year 2018: $1.47 billion | Fiscal year 2017: $812.70 million | Fiscal year 2016: $535.20 million | Fiscal year 2015: $809.10 million | Fiscal year 2014: $648.72 million | Fiscal year 2013: $535.61 million | Fiscal year 2012: $230.28 million | Fiscal year 2011: $483.61 million | Fiscal year 2010: $112.57 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: